Vapotherm scales up manufacturing capabilities to meet the potential increase in demand for its Precision Flow Hi-VNI system in the event of fresh waves of Covid-19 pandemic. Credit: UN Women / Pathumporn Thongking.

Vapotherm is set to scale up capital equipment manufacturing capabilities to increase the production of its Precision Flow systems.

The move is in response to an anticipated increase in demand for the company’s Precision Flow Hi-VNI system in the event of new waves of Covid-19 pandemic.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company intends to scale up the production by up to 20X above pre-Covid-19 pandemic levels with additional 350 manufacturing jobs at its New Hampshire, US, facility.

Vapotherm’s Precision Flow Hi-VNI system is an advanced high-flow nasal cannula (HFNC) system, which uses high velocity to treat respiratory distress related to Covid-19 disease.

It offers high flow at a high velocity, rapidly flushing the dead space in the limited time between breaths when respiratory rates are elevated.

A number of public health authorities and medical speciality societies, including Center for Disease Control (CDC), the National Institutes of Health (NIH), the Society of Critical Care Medicine (SCCM) and the American College of Emergency Physicians (ACEP) have recommended HFNC over early invasive mechanical ventilation when possible.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Commenting on the latest development, Vapotherm CEO Joe Army said: “The Covid-19 pandemic has greatly accelerated a process we were already seeing of respiratory experts recognising the benefits of our Precision Flow Hi-VNI system for treating patients with all types of respiratory distress.

“As hospitals and governments across the United States and around the world prepare for potential future waves of Covid-19 patients and subsequent pandemics, involving respiratory disease, we are expanding our manufacturing capabilities to be in a position to meet the needs of hospitals and patients for our therapy.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact